Amarin Reports First Notice of US Patent Allowance on ANCHOR Clinical Trial Results
Posted on January 23, 2013 at 11:30 AM EST
Amarin Corporation plc (Nasdaq: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notice of Allowance for Amarin's U.S. Patent Application Serial Number 12/815,569 titled "Compositions and Methods for Lowering Triglycerides